Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

This research study, called TroFuse-011, is investigating new ways to treat a specific type of breast cancer known as triple-negative breast cancer (TNBC). Doctors are looking at a new medicine called sacituzumab tirumotecan, given either on its own or together with another medicine called pembrolizumab. The main goal is to find out if these new treatments help people live longer overall, or if they can stop the cancer from growing or spreading for a longer period, compared to current chemotherapy treatments. The study involves comparing these new approaches to standard chemotherapy options like paclitaxel or a combination of gemcitabine and carboplatin. This is a Phase 3 study, meaning these treatments have previously shown promise and are now being tested in a larger group of people.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Einschreibeziel
1,000
Starten
16 Mar 2025
Geschätzte Fertigstellung
18 May 2030

Worum geht es in dieser Studie?

This study, known as TroFuse-011, is designed for people living with triple-negative breast cancer (TNBC). This type of breast cancer is called 'triple-negative' because it doesn't have the three most common markers that doctors look for. This means it doesn't respond to hormone therapies or treatments that target HER2 proteins. Finding effective treatments for TNBC is very important. Researchers want to see if new medicines can offer better options than the chemotherapy currently available.

The study focuses on a medicine called sacituzumab tirumotecan, which is being tested either by itself or alongside another medicine called pembrolizumab. Pembrolizumab is a type of immunotherapy that helps your body's immune system fight cancer. The main goal is to understand if these new approaches can help people live longer or stop the cancer from growing or spreading for a longer time, compared to standard chemotherapy treatments. This is a 'Phase 3' study, which means it’s one of the final steps in testing a new treatment, comparing it to established options to confirm its benefits and safety.

By comparing these new treatments with chemotherapy that is currently used, doctors hope to gather important information. This will help them decide if sacituzumab tirumotecan, either alone or with pembrolizumab, could become a new standard treatment option for people with TNBC. Taking part in such a study contributes to medical knowledge that can benefit many others in the future.

Wichtige Erkenntnisse

  • A study for triple-negative breast cancer (TNBC).
  • Testing new medicines: sacituzumab tirumotecan (alone or with pembrolizumab).
  • Compares new treatments to standard chemotherapy.
  • Aims to see if new treatments help people live longer or stop cancer growth longer.
  • This is a 'Phase 3' study, a crucial step in drug development.

Wer könnte berechtigt sein?

To join this study, you must be at least 18 years old and have triple-negative breast cancer that has come back in the local area or spread to other parts of your body, and can't be cured by surgery. You can't have received previous treatment for this advanced stage of breast cancer, though if you were treated for early-stage breast cancer, that's okay, as long as it was at least 6 months ago.

You should also generally be fit enough for treatment with pembrolizumab and standard chemotherapy options like paclitaxel. If you've had side effects from previous cancer treatments, these must have mostly cleared up. If you have hepatitis B or C, you might still be able to join if your virus levels are very low or undetectable with treatment.

However, you can't join if your breast cancer could still be cured with surgery. You also can't have certain other conditions, such as severe nerve damage (peripheral neuropathy), severe dry eyes or corneal issues, or active inflammatory bowel disease. If you've already received systemic treatment for your advanced breast cancer, you won't be eligible for this study.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre oder älter?
  2. Do you have triple-negative breast cancer that has spread or come back, and can't be cured by surgery?
  3. Have you NOT received other treatments for your advanced breast cancer yet?
  4. Are you generally well enough to receive immunotherapy and chemotherapy?
  5. Are you free from certain other health conditions like severe nerve damage or active inflammatory bowel disease?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, you would receive either sacituzumab tirumotecan alone, sacituzumab tirumotecan with pembrolizumab, or standard chemotherapy (such as paclitaxel or a combination of gemcitabine and carboplatin). The treatment will involve regular visits to the clinic for your medications and check-ups. Doctors and nurses will closely monitor your health, perform tests, and assess how well the treatment is working and if you're experiencing any side effects. You will also have regular follow-up appointments after your main treatment period. The exact duration of your participation will depend on the treatment assigned and your response, and your study team will provide you with a detailed schedule.

Potenzielle Risiken und Vorteile

Participating in a clinical trial may offer potential benefits, such as access to new treatments before they are widely available, and close medical monitoring. However, there are also potential risks; the new treatments might not work as expected, or they could cause side effects that are currently unknown or more severe than standard treatments. You might also be assigned to receive standard chemotherapy. It is important to remember that you are free to withdraw from the study at any time, for any reason, without affecting your current or future medical care.

Locations (285)

  • USA Mitchell Cancer Institute ( Site 0090)
    Verifizierte Postleitzahl
    Mobile, Vereinigte Staaten· Rekrutierung
  • Ironwood Cancer & Research Centers ( Site 0036)
    Verifizierte Postleitzahl
    Chandler, Vereinigte Staaten· Rekrutierung
  • City of Hope ( Site 0097)
    Verifizierte Postleitzahl
    Duarte, Vereinigte Staaten· Rekrutierung
  • City of Hope Lennar Foundation Cancer Center ( Site 0099)
    Verifizierte Postleitzahl
    Irvine, Vereinigte Staaten· Rekrutierung
  • UCLA Department of Medicine - Hematology & Oncology ( Site 0047)
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten· Rekrutierung
  • Yale New Haven Hospital ( Site 0001)
    Verifizierte Postleitzahl
    New Haven, Vereinigte Staaten· Abgeschlossen
  • Washington Hospital Center ( Site 0098)
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten· Rekrutierung
  • AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007)
    Verifizierte Postleitzahl
    Altamonte Springs, United States· Rekrutierung
  • Orlando Health Cancer Institute ( Site 0012)
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten· Rekrutierung
  • Florida Cancer Specialists - East ( Site 7000)
    Verifizierte Postleitzahl
    West Palm Beach, Vereinigte Staaten· Rekrutierung
  • University Cancer & Blood Center, LLC ( Site 0023)
    Verifizierte Postleitzahl
    Athen, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is 'triple-negative breast cancer'?

It's a type of breast cancer that doesn't have the three most common markers (estrogen receptors, progesterone receptors, and HER2 protein), meaning it's treated differently from other types of breast cancer.

What are sacituzumab tirumotecan and pembrolizumab?

These are new medicines being tested in this study. Sacituzumab tirumotecan is designed to deliver chemotherapy directly to cancer cells. Pembrolizumab is an immunotherapy that helps your immune system fight cancer.

Warum ist diese Studie wichtig?

It aims to find new, potentially more effective treatments for triple-negative breast cancer, which currently has fewer targeted treatment options compared to other breast cancer types.

Will I definitely get the new medicines if I join?

Not necessarily. You might receive sacituzumab tirumotecan alone, with pembrolizumab, or standard chemotherapy. It's decided randomly, like flipping a coin, so it's fair.

What does a 'Phase 3' study mean?

Phase 3 is the stage where a new treatment is compared to existing standard treatments in a larger group of people to see if it's better and safe enough to be approved.

Wie Sie mehr erfahren können

Gebührenfreie Nummer

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Mon… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.